Viking Therapeutics (VKTX) Stock: Buy, Sell, or Hold?
VKTX - Viking Therapeutics, Inc
$30.12
-0.39 (-1.28%)
▼
5d:
-15.3%
30d:
-10.09%
90d:
-22.19%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 28, 2026
25d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Sep 22, 2026 at $39.77 · last confirmed Sep 30, 2026
Strength: 6.6/10
Get Alerted When VKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VKTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VKTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VKTX is currently trading at $30.12, which is considered oversold relative to its 30-day fair value range of $30.16 to $36.00.
Technical Outlook: Technically, VKTX is showing sideways momentum. Immediate support is located at $28.40, while resistance sits at $43.10.
Market Sentiment: VKTX scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $94.82 (+210.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VKTX is showing sideways momentum. Immediate support is located at $28.40, while resistance sits at $43.10.
Market Sentiment: VKTX scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $94.82 (+210.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.16 -
$36.00
Company Quality Score
57/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (62/100)
- BULLISH: Trading 210.8% below Wall St target ($94.82)
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-15.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$30.16 -
$36.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$28.40
Resistance Level
$43.10
Current Trend
Sideways
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.93
Wall Street Target
$94.82
(+210.8%)
Share & Embed Analysis
Last updated: October 02, 2026 12:51 PM ET
Data refreshes hourly during market hours. Next update: 1:51 PM
Data refreshes hourly during market hours. Next update: 1:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
